AXV-101 clinical trials

First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration

This study is testing a new medicine, AXV-101, for young people (aged 4-17) with a specific genetic eye condition called Bardet-Biedl Syndrome 1 (BBS1). It aims to see if the medicine is safe and helps improve eyesight or slow down vision loss.